Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 years and over)

Document first published:
Page updated:
Topic:
Publication type:

Abatacept is recommended to be available as a treatment option through routine commissioning for refractory idiopathic inflammatory myopathies within the criteria set out in these documents. The policy is restricted to patients aged 2 years and over as per the drug’s licence in other indications.